Brainsway Ltd Sponsored ADR Stock

$13.22

0.92% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US10501L1061

Symbol

BWAY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Brainsway Ltd Sponsored ADR Stock price

$13.22

+7.33 124.45% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.12 0.92%

ISIN

US10501L1061

Symbol

BWAY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$247.0m

Enterprise Value

$181.0m

Net debt

$-66.0m

Cash

$71.6m

Shares outstanding

37.7m

Valuation (TTM | estimate)

P/E

188.86 | 33.82

P/S

5.68 | 1.33

EV/Sales

4.16 | 0.98

EV/FCF

22.60

P/B

7.83

Financial Health

Equity Ratio

66.07%

Return on Equity

4.69%

ROCE

2.25%

ROIC

13.19%

Debt/Equity

0.09

Financials (TTM | estimate)

Revenue

$43.5m | $185.2m

EBITDA

$3.7m | $6.2m

EBIT

$1.9m

Net Income

$3.9m | $14.8m

Free Cash Flow

$8.0m

Growth (TTM | estimate)

Revenue

26.85% | 351.49%

EBITDA

2,761.54% | 213.67%

EBIT

256.63%

Net Income

337.58% | 405.14%

Free Cash Flow

63.47%

Margin (TTM | estimate)

Gross

74.51%

EBITDA

8.57% | 3.37%

EBIT

4.32%

Net

9.01% | 7.97%

Free Cash Flow

18.43%

EPS

$0.07

FCF per Share

$0.21

Short interest

1.07%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Brainsway Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Brainsway Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	43 43	27% 27% 100%
- Direct Costs	11 11	26% 26% 25%
Gross Profit	32 32	27% 27% 75%
- Selling and Administrative Expenses	23 23	12% 12% 52%
- Research and Development Expense	7.90 7.90	22% 22% 18%
EBITDA	3.72 3.72	2,762% 2,762% 9%
- Depreciation and Amortization	1.85 1.85	39% 39% 4%
EBIT (Operating Income) EBIT	1.88 1.88	257% 257% 4%
Net Profit	3.92 3.92	338% 338% 9%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Brainsway Ltd Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

17 days ago

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial

Neutral

GlobeNewsWire

●

18 days ago

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

Neutral

GlobeNewsWire

●

24 days ago

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care

More Brainsway Ltd Sponsored ADR News

Company Profile

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Head office	Israel
CEO	Mr. Levy
Founded	2006
Website	www.brainsway.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now